On 5/1/24, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a major increase of 10.7%, closing at $4.57. Moreover, this advance was accompanied by unusually high trading volume at 157% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 4.3% during the last week.
Current PriceTarget Research Rating
BCRX is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.